Premium
Human herpesvirus portal proteins: Structure, function, and antiviral prospects
Author(s) -
Kornfeind Ellyn M.,
Visalli Robert J.
Publication year - 2018
Publication title -
reviews in medical virology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.06
H-Index - 90
eISSN - 1099-1654
pISSN - 1052-9276
DOI - 10.1002/rmv.1972
Subject(s) - capsid , biology , dna , genome , virology , viral replication , bacteriophage , dna replication , function (biology) , virus , phagemid , computational biology , microbiology and biotechnology , genetics , gene , escherichia coli
Summary Herpesviruses ( Herpesvirales ) and tailed bacteriophages ( Caudovirales ) package their dsDNA genomes through an evolutionarily conserved mechanism. Much is known about the biochemistry and structural biology of phage portal proteins and the DNA encapsidation (viral genome cleavage and packaging) process. Although not at the same level of detail, studies on HSV‐1, CMV, VZV, and HHV‐8 have revealed important information on the function and structure of herpesvirus portal proteins. During dsDNA phage and herpesviral genome replication, concatamers of viral dsDNA are cleaved into single length units by a virus‐encoded terminase and packaged into preformed procapsids through a channel located at a single capsid vertex (portal). Oligomeric portals are formed by the interaction of identical portal protein monomers. Comparing portal protein primary aa sequences between phage and herpesviruses reveals little to no sequence similarity. In contrast, the secondary and tertiary structures of known portals are remarkable. In all cases, function is highly conserved in that portals are essential for DNA packaging and also play a role in releasing viral genomic DNA during infection. Preclinical studies have described small molecules that target the HSV‐1 and VZV portals and prevent viral replication by inhibiting encapsidation. This review summarizes what is known concerning the structure and function of herpesvirus portal proteins primarily based on their conserved bacteriophage counterparts and the potential to develop novel portal‐specific DNA encapsidation inhibitors.